Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)

Inclusion Criteria: * Patient had at least a 6-month history of migraine, with or without aura * Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions. * Patient was judged to be in good health, apart from migraine Exclusion Criteria: * Patient was pregnant or a nursing mother * Patient had abused drugs or alcohol within 12 months prior to entering the study * Patient had a history of cardiovascular disease * Patient had clinically significant Electrocardiography (ECG) abnormality * Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening * Patient received treatment with an investigational device or compound within 30 days of the study start * Patient typically suffered from less then 1 or more than 8 attacks of migraine per month * Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches * Patient had hypersensitivity to sumatriptan * Patient had participated in any previous study involving rizatriptan